Search Results for “acquisition” – Page 10 – media

Merger of two well-known pharmaceutical companies

On October 7, Jiahe Bio announced that it would acquire Yitong Pharmaceuticals by merger. The name of the merged company will be changed to Yitong Jiahe Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Yitong Jiahe”). The transaction is carried out in the form of a share swap. The price of the proposed merger will be fully settled by issuing consideration shares. After the merger is completed, the shareholders of both parties will jointly hold the equity of Yitong Jiahe, and Jiahe Bio will not have any cash expenditure. According to the listing rules, the transaction constitutes a reverse acquisition of Jiahe Bio. In the merged Yitong Jiahe, the original Yitong Pharmaceutical shareholders accounted for 77.43%, and the original Jiahe Bio shareholders accounted for 22.57%. The actual controller of Yitong Pharmaceutical will become the controlling shareholder of Yitong Jiahe. Based on the rules of Chapter 18A of the Hong Kong ...
- Source: drugdu
- 70
- October 10, 2024
Cardiovascular device giant, official announcement of split

Recently, Integer Holdings Corporation, the world’s largest CDMO company with deep roots in cardiovascular devices, announced that it will divest its non-medical business. The company has reached an agreement to sell its Electrochem business, which focuses on the energy, military and environmental fields, to Ultralife Corporation for $50 million in cash, and the transaction is expected to be completed by the end of October. Joe Dziedzic, president and CEO of Integer, said that after the transaction is completed, Integer will be a pure medical company with additional cash to repay debt and execute our inorganic growth strategy. Ultralife is an ideal buyer for Electrochem because they are a leader in providing critical power solutions to a variety of industries including energy, defense and environmental markets. As a global medical device CDMO leader, Integer’s medical customers include large multinational medical device OEMs and their subsidiaries, including Abbott, Johnson & Johnson, Boston ...
- Source: drugdu
- 69
- October 9, 2024
With a dividend rate of 100% and a profit growth rate of nearly 40%, Dong-E-E-Jiao has resumed high growth

In recent days, various stimulus policies designed from the top have been launched, giving the long-dull stock market a long-lost vitality. On September 30, the Shanghai Composite Index closed up 8.06%, standing above 3,300 points, with a cumulative increase of more than 17% in September; the Shenzhen Component Index closed up 10.67%, with a cumulative increase of more than 26% in September; the ChiNext Index closed up 15.36%, with a cumulative increase of more than 37% in September; all set a record for the largest single-day increase in history. On that day, the turnover of the two markets was 2.593 trillion yuan, setting a record high since 2006. The activity of funds has risen unprecedentedly, and once exceeded the carrying capacity of the exchange server during the session. Players in the market are gearing up to “do a big job”. However, the pharmaceutical industry has been subject to many restrictions ...
- Source: drugdu
- 74
- October 9, 2024
Electrophysiology, giants dance wildly

The existing electrophysiology market is very considerable, and the incremental market has unlimited potential. Research institution BTIG predicts that half of atrial fibrillation ablations may be replaced by PFA in the next three years. In the new business of PFA, electrophysiology giants dare not be tired at all. Recently, Boston Scientific announced that it has obtained approval from Japanese regulators for the FARAPULSE™ pulsed field ablation system. Nick Spadea-Anello, president of Boston Scientific Electrophysiology, said that the FARAPULSE PFA system is the most clinically studied PFA system. To date, it has been used to treat more than 125,000 patients worldwide and continues to strengthen its strong safety, effectiveness and efficiency characteristics. “The rapid adoption of the FARAPULSE PFA system, which is now approved in more than 65 countries, demonstrates a paradigm shift in the treatment of paroxysmal atrial fibrillation – an approach that has clinical benefits for both physicians and ...
- Source: drugdu
- 77
- October 8, 2024
What does it mean to have a dual system in healthcare?

On September 8, the Ministry of Commerce, the National Health Commission, and the State Food and Drug Administration jointly issued the Notice on Carrying out Pilot Work on Expanding Opening-up in the Medical Field (hereinafter referred to as the “Notice”). It is proposed to allow the establishment of wholly foreign-owned hospitals (except for traditional Chinese medicine, excluding mergers and acquisitions of public hospitals) in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan. This is undoubtedly a bold innovation to the existing healthcare system. Previously, foreign investment was limited to joint venture hospitals, and there were many restrictions such as shareholding ratio. With the relaxation of policy restrictions and the introduction of foreign-funded medical institutions, as more high-end medical institutions enter the Chinese market, while diverting some high-end patients, it may also improve the development and progress of the overall medical level in China. There are two main points ...
- Source: drugdu
- 89
- October 6, 2024
What is the impact of the House of Representatives’ passage of the draft biosafety law amid the controversy on WuXi

On September 9, the House of Representatives of the United States Congress returned from a summer break and immediately scheduled a series of legislative votes, including the draft Biosafety Act (H.R. 8333). The draft biosecurity law passed the House of Representatives with 306 votes in favor and 81 votes against, but the 70% support rate made it the most divisive draft bill in the same batch, and even narrowly fell below the “bottom line” of more than two-thirds of the votes to pass the bill. The draft Biosafety Act places five companies, including WuXi AppTec and WuXi Biologics, on the list of “biotechnology companies of concern” on the grounds of “national security”, and intends to restrict the use of funds, loans or subsidies from the United States government to cooperate with these companies. Unlike previous committees that voted in small groups, this time there were several members of the House ...
- Source: drugdu
- 80
- October 6, 2024
Medtronic, new progress in ECMO

On September 26, Medtronic’s official website announced the launch of a new ECMO system called VitalFlow™. This is a configurable single-system ECMO solution built on simplicity and performance. According to the official website, the VitalFlow system has a large, intuitive touch screen that centrally displays real-time performance data, provides configurability, and uses the proven Medtronic Nautilus™ ECMO oxygenator design to achieve long-term stable performance. Medtronic said that the VitalFlow™ ECMO system bridges the gap between bedside care and in-hospital transportation, providing clinicians with an easier and smarter ECMO experience. Dr. Karim Bandali, president of the cardiac surgery business within the Medtronic cardiovascular product portfolio, believes that the VitalFlow system is simple and easy to use, allowing users with different comfort levels to serve patients confidently and efficiently. It can be easily moved between different departments of the hospital and has durable and reliable performance. In March 2024, Medtronic completed ...
- Source: https://mp.weixin.qq.com
- 105
- October 4, 2024
Over 3 billion, Stone Pharmaceutical Group reached a major cooperation

On September 29, Shi Pharma Group signed an exclusive licensing agreement with Jiangsu Conri Pharma on the development and commercialization of JSKN003 in mainland China. JSKN003 is a HER2-targeting bispecific antibody-drug conjugate (ADC) with dual HER2 targeting, giving it stronger internalization induction and bystander killing effects, making it highly active against HER2-expressing tumors. Currently, JSKN003 is undergoing Phase I clinical trials in Australia and Phase I/II and Phase III clinical trials in China. Next, Jinmant Bio (a wholly-owned subsidiary of Chiatai Tianqing Pharmaceutical Group) will be granted exclusive license and sublicensing rights for the development, sales, promised sales, and commercialization of the product. They will bear all clinical development costs and become the sole marketing authorization holder for JSKN003 in Mainland China for that field. According to the agreement, Corning Jerry has the right to receive a total of up to 3.08 billion RMB in upfront and milestone payments, including ...
- Source: https://mp.weixin.qq.com
- 98
- October 2, 2024
A historic night in the treatment of schizophrenia

On September 26, the field of schizophrenia ushered in a historic moment, when KarXT developed by Karuna was approved by the FDA for marketing. This means that Bristol-Myers Squibb’s tens of billions of bets have succeeded in their first battle. On December 22 last year, Bristol-Myers Squibb spent $14 billion to acquire Karuna for KarXT. KarXT has been approved for marketing, and there is another winner – Zai Lab. Currently, Zai Lab owns the rights to KarXT in Greater China. Considering that there are more than 8 million schizophrenia patients in China, and the introduction cost of Zai Lab is not high, it is expected to obtain sufficient profits. Of course, all this can only be said to have settled, and is not surprising. Most of the existing schizophrenia treatments are old varieties approved in the 1990s. KarXT does not rely on dopaminergic or serotonergic pathways and is the first ...
- Source: drugdu
- 70
- September 30, 2024
Medtronic and Siemens Healthineers reach a major collaboration

On September 25, local time, at the 39th Annual Meeting of the North American Spine Society (NASS) held in Chicago, Medtronic announced that it has established a partnership with Siemens Healthineers to explore opportunities to further expand advanced preoperative and postoperative imaging technologies for spine care. Medtronic and Siemens Healthineers plan to bring the Siemens Healthineers Multitom Rax™ imaging system to market and integrate the platform into Medtronic’s spine surgery AiBLE™ ecosystem. The two companies also hope to collaborate on technology development, marketing and commercial activities to improve clinical outcomes. Multitom Rax™ can be used for musculoskeletal diseases, including spinal patients. Multitom Rax™ features standing, weight-bearing imaging, cone beam CT and supine x-ray capabilities, supporting Medtronic’s commitment to improving standards of care across the care continuum. Skip Kiil, president of Medtronic CranioSpinal Technology, said: “The collaboration with Siemens Healthineers advances our commitment to reduce variability and improve outcomes for spinal ...
- Source: drugdu
- 71
- September 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.